EcoDrugPlus

Estrogen Receptor 2

Ensembl ID : ENSOKIG00005017780
Gene Symbol: ESR2
1 Cross references
204 Possible Orthologues:

Estrogen Receptor Beta

Ensembl ID : ENSOKIG00005038442
Gene Symbol: LOC109894436
3 Cross references
203 Possible Orthologues:

Estrogen Receptor Beta

Ensembl ID : ENSOKIG00005003323
Gene Symbol: LOC109900844
3 Cross references
198 Possible Orthologues:

Estrogen Receptor-Like

Ensembl ID : ENSOKIG00005019289
Gene Symbol: LOC109900320
2 Cross references
208 Possible Orthologues:

Farnesyl Pyrophosphate Synthase

Ensembl ID : ENSOKIG00005042522
Gene Symbol: LOC109882340
3 Cross references
263 Possible Orthologues:

Farnesyl Pyrophosphate Synthase-Like

Ensembl ID : ENSOKIG00005000578
Gene Symbol: LOC109887305
3 Cross references
263 Possible Orthologues:

Farnesyl-Diphosphate Farnesyltransferase 1

Ensembl ID : ENSOKIG00005015873
Gene Symbol: FDFT1
3 Cross references
220 Possible Orthologues:

Farnesyltransferase, Caax Box, Alpha

Ensembl ID : ENSOKIG00005025762
Gene Symbol: FNTA
3 Cross references
215 Possible Orthologues:

Farnesyltransferase, Caax Box, Beta

Ensembl ID : ENSOKIG00005031051
Gene Symbol: FNTB
1 Cross references
203 Possible Orthologues:

Fibroblast Growth Factor Receptor 1

Ensembl ID : ENSOKIG00005029321
Gene Symbol: FGFR1
3 Cross references
198 Possible Orthologues:

Fibroblast Growth Factor Receptor 1

Ensembl ID : ENSOKIG00005041930
Gene Symbol: FGFR1
3 Cross references
197 Possible Orthologues:

Fibroblast Growth Factor Receptor 1a

Ensembl ID : ENSOKIG00005008747
Gene Symbol: FGFR1A
1 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).